Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases. Leveraging its precision data analytics and a multi-platform approach, Alumis is advancing a pipeline of oral therapies designed to address immune dysfunction.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/06/24 | $259,000,000 | Series C |
Ally Bridge Group AyurMaya Cormorant Asset Management Foresite Capital  HBM Healthcare Investments Lilly Asia Ventures Nextech Ventures Omega Funds Piper Heartland Healthcare Capital Samsara BioCapital SR One VenBio | undisclosed |
